Omnes Capital

Omnes Capital, established in 1999, is a prominent Paris-based private equity firm with €4.8 billion in assets under management. It specializes in providing growth capital to innovative small and medium-sized enterprises (SMEs), with a focus on technology and healthcare sectors. The firm has a proven track record, having supported over 120 companies and facilitated 65 business exits, including 14 initial public offerings (IPOs), over the past 16 years. Omnes Capital's expertise spans venture capital, buyout & growth capital, private debt, renewable energy, and co-investment strategies, making it a key player in France's private equity landscape.

Benjamin Arm

Managing Partner

Guillaume Blavier

Associate, Deeptech

Guillaume Blavier

Associate

Xavier Brunaud

Director, Venture Capital

Romain Campi

Principal

Antoine Colboc

Head of Venture Capital

Fabien Collangettes

Director of Investments

François-Xavier Dedde

Director

Jean-Baptiste Delattre

Principal

Julie Delclaux

Associate

Delibes Camille

Partner

Rémy Deloffre

Associate

Simon Hardi

Partner

Morgane Honikman

Director

Morgane Honikman

Partner

Hugo Hubert

Principal, Deeptech

Antoine Joris

Principal

Maia Korradi

Principal

Yasmine Lazrak

Principal

Camille Léonard

Associate

Laurent Perret

Principal and Director of investments

Claire Poulard

Principal

Renaud Poulard

Partner

Fabien Prevost

Chief Investment Officer and Chairman

Sylvia Raussin

Investment Manager

Eric Rey

Managing Partner

Benjamin Stremsdoerfer

Partner

Aymeric de Susbielle

Associate

Philippe Trolez

Corporate Secretary, Partner and Member of the Executive Committee

Yannic Trueb

Principal

Gonzague de Trémiolles

Investment Director

Caroline Yametti

Director

287 past transactions

VSORA

Venture Round in 2025
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

ARX Robotics

Series A in 2025
ARX is a defense technology company that specializes in the development of autonomous unmanned systems for dual-use applications.

Sekoia.io

Series B in 2025
Sekoia.io develops a unified security platform aimed at enhancing the capabilities of security operations (SecOps) teams in combating cyber threats. The platform enables organizations to automatically identify and respond to significant incidents across their entire attack surface, leveraging integrated intelligence and real-time detection. By continuously analyzing emerging threats, Sekoia.io equips clients with the necessary strategies to stay updated and effectively address new challenges. Its approach allows security teams to manage the complexities of cybersecurity with improved speed and reliability, ultimately strengthening their overall security posture.

Coave Therapeutics

Series A in 2025
Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Planet A Foods

Series B in 2024
Planet A Foods is a company focused on producing cocoa-free chocolate made from natural ingredients. By utilizing traditional fermentation methods, the company aims to provide a sustainable alternative to traditional chocolate, allowing consumers to enjoy their chocolate cravings without the negative impacts associated with cocoa production. Planet A Foods emphasizes local food production with minimal environmental impact, striving to reduce carbon emissions and promote sustainable practices in the food industry.

The Exploration Company

Series B in 2024
The Exploration Company specializes in the development, manufacturing, and operation of modular and reusable spacecraft known as Nyx, which are intended for use in orbit around Earth and the Moon. These vehicles are designed to be refueled in space and incorporate environmentally friendly propellants. By offering an open-source operating system for Nyx, the company aims to democratize space exploration, making it more accessible to new entrants in the field. The Exploration Company focuses on providing cost-effective solutions for in-space experiments, allowing participants to engage in space exploration at a fraction of the cost associated with traditional platforms like the International Space Station.

Qantev

Series B in 2024
Qantev operates an AI-driven health claims platform designed for health and life insurance companies. The platform utilizes a proprietary algorithm to enhance the configuration of provider networks and identify optimal participants, thereby assisting insurers in minimizing claims leakage. By leveraging historical claims data, Qantev's technology empowers health insurance teams to gain valuable insights, facilitating data-driven decision-making and the development of effective business strategies. This innovative approach aims to improve efficiency and accuracy in claims operations across the global insurance market.

Carbyon

Series A in 2024
Carbyon is a Netherlands-based company specializing in direct air capture (DAC) technologies that filter carbon dioxide (CO2) from ambient air. Its innovative "fast-swing" technology purifies CO2, making it suitable for various applications, including the production of kerosene for aircraft. By enabling the fossil fuel industry to repurpose existing storage and transportation infrastructure for renewable hydrocarbons, Carbyon supports the transition from fossil hydrocarbons to alternative energy carriers, such as batteries and hydrogen. This approach not only aids in reducing greenhouse gas emissions but also facilitates significant transformations in energy systems and transportation networks.

Unseenlabs

Series C in 2024
Unseenlabs is a French company based in Rennes, founded in 2015, that specializes in marine surveillance services utilizing satellite technology. The company develops spectrum surveillance payloads that enable the detection and tracking of non-cooperative vessels globally. By launching satellites equipped to detect and geolocate signals and electromagnetic waves emitted by ships, Unseenlabs can identify vessels even if they disable their Automatic Identification System beacon. This capability allows clients to monitor maritime activities and locate boats engaged in illegal operations, such as illegal fishing, degassing, and maritime piracy. Unseenlabs provides comprehensive solutions that encompass satellite design and launch, ensuring effective maritime monitoring from space.

EEF Erneuerbare Energien Fabrik

Acquisition in 2024
EEF Erneuerbare Energien Fabrik is a power generation company specializing in renewable energy. It develops, implements, and operates wind energy and photovoltaic projects, along with energy storage solutions, to facilitate the decarbonization of the energy market. The company also employs AI software to enhance its operations.

GEEV

Venture Round in 2024
GEEV is a mobile application that facilitates the donation and collection of various objects among its users, promoting a collaborative anti-waste initiative. It allows members to either give away items they no longer need or to obtain free objects from others, thereby encouraging sustainable practices and reducing waste. The platform includes features that enable users to communicate easily, arrange meetings, and effectively exchange items, fostering a community-driven approach to sharing resources. By connecting individuals who wish to donate with those seeking to obtain, GEEV aims to give a second life to usable items while minimizing environmental impact.

Planet A Foods

Series A in 2024
Planet A Foods is a company focused on producing cocoa-free chocolate made from natural ingredients. By utilizing traditional fermentation methods, the company aims to provide a sustainable alternative to traditional chocolate, allowing consumers to enjoy their chocolate cravings without the negative impacts associated with cocoa production. Planet A Foods emphasizes local food production with minimal environmental impact, striving to reduce carbon emissions and promote sustainable practices in the food industry.

Quandela

Series B in 2023
Quandela is a company specializing in quantum computing, focusing on the development of communication networks and optical computers. It manufactures photonic quantum computers and markets them to industrial clients. The company's flagship product, a single-photon source device, integrates photonics with semiconductor quantum dots, facilitating quantum communication, computation, and sensing. This device allows for the efficient collection of emitted single photons at high rates, helping researchers minimize charge noise decoherence and achieve the emission of identical photons with high fidelity. These advancements are crucial for the progress of sophisticated quantum applications, positioning Quandela as a key player in the field of quantum technology.

Quantum Systems

Series B in 2023
Quantum system develops manufactures and sells unmanned aerial systems, which provide aerial intelligence to commercial and governmental clients around the world.

Corteria Pharmaceuticals

Series A in 2023
Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

PeopleSpheres

Venture Round in 2023
PeopleSpheres is a Paris-based company that specializes in providing human resources management software solutions. Founded in 2010 and formerly known as NeoSpheres SAS, the company rebranded to PeopleSpheres in September 2019. Recognizing a gap in the market for tailored HR management solutions, PeopleSpheres developed a customizable and scalable platform designed to meet the diverse needs of businesses. The company collaborates with leading national HR service providers to better serve American enterprises, ensuring that its offerings are both suitable and sustainable for a wide range of clients. As of September 2019, PeopleSpheres operates as a subsidiary of Sopra HR Software SAS.

Sekoia.io

Series A in 2023
Sekoia.io develops a unified security platform aimed at enhancing the capabilities of security operations (SecOps) teams in combating cyber threats. The platform enables organizations to automatically identify and respond to significant incidents across their entire attack surface, leveraging integrated intelligence and real-time detection. By continuously analyzing emerging threats, Sekoia.io equips clients with the necessary strategies to stay updated and effectively address new challenges. Its approach allows security teams to manage the complexities of cybersecurity with improved speed and reliability, ultimately strengthening their overall security posture.

Diogenx

Series A in 2023
DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

Iktos

Series A in 2023
Iktos is a French company focused on artificial intelligence and robotic solutions for medicinal chemistry and drug design. It offers a proprietary generative AI technology that optimizes molecule design for small molecule discovery projects, significantly enhancing productivity in pharmaceutical research and development. Iktos provides its innovative solutions through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also engaging in strategic partnerships with pharmaceutical companies to accelerate drug discovery. Additionally, Iktos has developed an AI-driven synthesis automation platform, Iktos Robotics, which expedites the Design-Make-Test-Analyze cycle in drug development. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In March 2023, Iktos secured a significant financing round, and in July 2024, it enhanced its capabilities by acquiring Synsight, which adds a biology platform for discovering drugs targeting Protein-Protein and RNA-Protein interactions.

The Exploration Company

Series A in 2023
The Exploration Company specializes in the development, manufacturing, and operation of modular and reusable spacecraft known as Nyx, which are intended for use in orbit around Earth and the Moon. These vehicles are designed to be refueled in space and incorporate environmentally friendly propellants. By offering an open-source operating system for Nyx, the company aims to democratize space exploration, making it more accessible to new entrants in the field. The Exploration Company focuses on providing cost-effective solutions for in-space experiments, allowing participants to engage in space exploration at a fraction of the cost associated with traditional platforms like the International Space Station.

VSORA

Venture Round in 2023
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

Opensee

Series A in 2022
Opensee is a Paris-based fintech company focused on providing self-service analytics solutions for financial institutions. Founded by experts from the financial and technology sectors, Opensee addresses the challenges of managing vast amounts of data by enabling business users to directly access and analyze their information on demand. This capability allows institutions to conduct in-depth analysis and what-if scenarios on billions of data points, improving efficiency and responsiveness to regulatory and business needs. The platform empowers financial organizations to manage risk in capital markets, streamline resources in commercial and retail banking, and enhance market intelligence through better utilization of transaction data. By transforming big data challenges into competitive advantages, Opensee aims to support financial institutions in making informed decisions swiftly and effectively.

Dust Mobile

Series B in 2022
Dust Mobile is a mobile operator based in Brussels, Belgium, specializing in cyber security solutions for voice, text, and data communications. Established in 2017, the company focuses on protecting its clients from threats associated with cellular network signaling protocols across various technologies, including 2G, 3G, 4G LTE, and 5G. Dust Mobile offers comprehensive services that include encryption for voice, SMS, and data communications, as well as cyber security for mobile networks and transmission. Its mission is to provide secure and resilient mobile communication services to businesses, critical operations, and organizations worldwide, especially for individuals and connected devices that are vulnerable to cyber-attacks. Founded by a team with extensive expertise in defense, security, electronic warfare, and telecommunications, Dust Mobile aims to defend critical communications against an evolving landscape of cyber threats.

Qantev

Series A in 2022
Qantev operates an AI-driven health claims platform designed for health and life insurance companies. The platform utilizes a proprietary algorithm to enhance the configuration of provider networks and identify optimal participants, thereby assisting insurers in minimizing claims leakage. By leveraging historical claims data, Qantev's technology empowers health insurance teams to gain valuable insights, facilitating data-driven decision-making and the development of effective business strategies. This innovative approach aims to improve efficiency and accuracy in claims operations across the global insurance market.

Gourmey

Series A in 2022
Gourmey is a cultivated meat company based in Paris, France, founded in 2019. It specializes in producing ethical foie gras derived from duck cells, offering a sustainable alternative to traditional methods that involve force-feeding and slaughter. By cultivating animal cells in a controlled laboratory environment, Gourmey creates meat products that prioritize health, environmental sustainability, and animal welfare. The company aims to provide delicious meat options for consumers who are conscious of their choices and seek innovative solutions in the food industry.

Ternoa

Seed Round in 2022
Ternoa is a technology company based in Biarritz, Nouvelle-Aquitaine, France, specializing in blockchain solutions for secure and anonymous data transfer. Founded in 2013, Ternoa's innovative technology facilitates digital transmission, allowing users to safely store and manage encrypted data through decentralized storage providers. By employing multi-party cryptography, the company ensures the long-term integrity of data, particularly in the context of non-fungible tokens (NFTs). Ternoa's approach eliminates the need for intermediaries, enabling seamless and secure access to digital information for users worldwide.

WhiteLab Genomics

Seed Round in 2022
WhiteLab Genomics is a biotechnology company that has developed a proprietary platform utilizing graph knowledge technology and machine learning to support the discovery and design of new genomic therapies. By providing a comprehensive database, the platform allows scientists to conduct detailed analyses of various datasets, facilitating solutions to critical scientific and technical challenges. These include optimizing plasmid and vector design, assessing genotoxicity, and identifying effective experimental protocols for both in vivo and in vitro applications. WhiteLab Genomics focuses on guiding clients through the in-silico development phases, enabling them to efficiently create target vectors and payloads. This streamlined approach not only saves time but also accelerates the delivery of innovative genomic therapies to patients.

Qubit Pharmaceuticals

Seed Round in 2022
Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Therapixel

Series B in 2022
Therapixel SA is a French company specializing in the development of artificial intelligence-based medical image analytics software aimed at enhancing surgical procedures. Founded in 2013 and headquartered in Valbonne, France, Therapixel offers a range of products designed to assist healthcare professionals, including Radvise, an automatic image reading solution; Fluid, a touchless navigation system for surgical environments; Anywhere, a post-processing workstation; and CD-Feed, a solution for importing outpatient imaging exams. The company's technology focuses on providing timely and relevant information to surgeons, ensuring they can access critical medical images before or during surgical operations. With additional locations in various countries, including Australia, China, and several nations across Europe and Latin America, Therapixel is committed to improving breast cancer detection and characterization through its innovative software solutions.

Domain Therapeutics

Series A in 2022
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

TagEnergy

Venture Round in 2022
TagEnergy is a clean energy enterprise for a new cycle in the renewable energy industry. It was formed in 2019 to accelerate the energy transition by developing and investing in competitive and clean power stations in order to compete directly and actively on the energy markets. Renewables have now become the main source of energy able to provide both social responsibility and price efficiency, and we are delivering this in the countries where we have established our activity. ​TagEnergy is operated by a highly-experienced team of manager-shareholders. Its operations span the renewables value chain, from development, financing, construction and asset management of wind, solar and storage projects, to commercialisation of its competitive energy. TagEnergy has developed a portfolio of 2.7GW in the UK, Australia, Spain, Portugal and France, and intends to drive the pace of transition through projects that deliver reliable energy affordably, and at scale.

Skillup

Venture Round in 2022
Skillup is an educational training and talent management platform that assists companies in researching, comparing, and booking professional training courses. With a database featuring over 20,000 training options and 50,000 reviews, it serves as a comprehensive resource for HR services seeking suitable training for employees. The platform includes a reservation engine and online publication features, along with software tools that streamline the management of training programs, interviews, and skills assessments. By optimizing these processes, Skillup enables employers and HR managers to focus on strategic talent engagement, growth, and retention.

SeqOne Genomics

Series A in 2022
Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGS has had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.

AlgoTherapeutix

Series B in 2022
AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

Corteria Pharmaceuticals

Seed Round in 2021
Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

Quandela

Venture Round in 2021
Quandela is a company specializing in quantum computing, focusing on the development of communication networks and optical computers. It manufactures photonic quantum computers and markets them to industrial clients. The company's flagship product, a single-photon source device, integrates photonics with semiconductor quantum dots, facilitating quantum communication, computation, and sensing. This device allows for the efficient collection of emitted single photons at high rates, helping researchers minimize charge noise decoherence and achieve the emission of identical photons with high fidelity. These advancements are crucial for the progress of sophisticated quantum applications, positioning Quandela as a key player in the field of quantum technology.

Coave Therapeutics

Series B in 2021
Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Prima Vital

Seed Round in 2021
Prima Vital provides financing advice and assistance, delivery and installation of safety equipment, after-sales service, and warranty and maintenance of installations. Their customers' inquiries are addressed through phone, email, and online applications.

Ilmatar Energy

Venture Round in 2021
Ilmatar is a project-oriented integrator in the renewable energy sector, primarily focusing on the development, construction, and operation of onshore wind farms. The company aims to build 1 GW of new wind power capacity in Finland over the next five years, significantly contributing to the reduction of carbon dioxide emissions and promoting a cleaner energy future. Ilmatar identifies, develops, finances, constructs, and operates renewable energy sites while also exploring new carbon-neutral technologies. The company engages in long-term Power Purchase Agreements (PPAs) to provide stable energy supplies. With a commitment to sustainability, Ilmatar collaborates with a network of domestic and international partners, including Omnes Capital and EDF Renewables, while local companies handle project development and operations.

Unseenlabs

Series B in 2021
Unseenlabs is a French company based in Rennes, founded in 2015, that specializes in marine surveillance services utilizing satellite technology. The company develops spectrum surveillance payloads that enable the detection and tracking of non-cooperative vessels globally. By launching satellites equipped to detect and geolocate signals and electromagnetic waves emitted by ships, Unseenlabs can identify vessels even if they disable their Automatic Identification System beacon. This capability allows clients to monitor maritime activities and locate boats engaged in illegal operations, such as illegal fishing, degassing, and maritime piracy. Unseenlabs provides comprehensive solutions that encompass satellite design and launch, ensuring effective maritime monitoring from space.

PeopleSpheres

Venture Round in 2021
PeopleSpheres is a Paris-based company that specializes in providing human resources management software solutions. Founded in 2010 and formerly known as NeoSpheres SAS, the company rebranded to PeopleSpheres in September 2019. Recognizing a gap in the market for tailored HR management solutions, PeopleSpheres developed a customizable and scalable platform designed to meet the diverse needs of businesses. The company collaborates with leading national HR service providers to better serve American enterprises, ensuring that its offerings are both suitable and sustainable for a wide range of clients. As of September 2019, PeopleSpheres operates as a subsidiary of Sopra HR Software SAS.

Elistair

Series B in 2021
Elistair SAS specializes in the design and manufacture of industrial tethered drone systems, enhancing the capabilities of unmanned aerial vehicles (UAVs) for a variety of applications. Founded in 2014 and based in Champagne-au-Mont-d'Or, France, the company provides products such as SAFE-T and LIGH-T, which deliver real-time observation and aerial monitoring capabilities. These systems are valued for their extended flight times, enhanced safety, and secure data transfer, making them ideal for use by police forces, public safety departments, private security firms, and government agencies across more than 30 countries. Elistair has received recognition for its innovative contributions to the industry, including the 2016 Technology Innovation Award from Frost & Sullivan.

Artifakt

Series A in 2021
Artifakt is a developer of cloud application tools that streamline the deployment, management, and operation of web projects on modern cloud infrastructures. The company's solutions allow digital teams to autonomously deploy and maintain their web applications, significantly reducing the complexity and time involved in cloud deployment. By enabling developers to configure environments quickly and automate various processes, Artifakt empowers them to concentrate on writing, testing, and enhancing their code. This focus ultimately allows developers to return to their core passion of building innovative solutions.

AgomAb Therapeutics

Series B in 2021
AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Bizay

Series C in 2020
BIZAY operates a digital marketplace that specializes in customizable products, catering to a diverse range of customers across Europe and the Americas. The company offers the world's largest catalogue of customizable items, allowing local manufacturers, brands, and wholesalers to deliver personalized products efficiently. Its platform targets various customer segments, including B2B2C businesses, small and medium-sized enterprises, and major brands seeking customized solutions. BIZAY’s extensive offerings encompass promotional items, packaging, home and garden goods, fashion products, and beauty items. The company emphasizes sustainability and social responsibility by collaborating with partners focused on inclusion and utilizing recycled materials in production. BIZAY employs advanced supply-chain optimization technologies to significantly reduce production costs, empowering clients to enhance their marketing strategies through innovative customization options.

AlgoTherapeutix

Series A in 2020
AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

Power Capital Renewable Energy

Acquisition in 2020
Power Capital Renewable Energy Limited, founded in 2011 and based in Dublin, Ireland, focuses on the development, operation, and management of large-scale photovoltaic solar farms. The company specializes in all four stages of a solar asset's life cycle, including design, development, financing, construction, and operation. By acquiring and managing utility-scale solar parks, Power Capital aims to provide clean and reliable energy, contributing to the sustainability of the renewable energy sector. Their commitment to delivering competitive and sustainable energy solutions positions them as a significant player in the renewable energy market.

Biosyl

Venture Round in 2020
Biosyl SAS is a holding company based in Cosne-Cours-sur-Loire, France, founded in 2010. Through its subsidiary, the company specializes in the production of wood pallets for domestic stoves and pallet boilers. Biosyl focuses on transforming waste and wood waste into energy, specifically low-emission wood pellets. The company operates a pellet production plant that processes logs and has the capacity to produce over one hundred thousand tons of pellets annually. This production not only supports local coppice wood recovery but also enables customers to reduce their carbon footprint by utilizing energy derived from low CO2 emissions.

Sekoia.io

Series A in 2020
Sekoia.io develops a unified security platform aimed at enhancing the capabilities of security operations (SecOps) teams in combating cyber threats. The platform enables organizations to automatically identify and respond to significant incidents across their entire attack surface, leveraging integrated intelligence and real-time detection. By continuously analyzing emerging threats, Sekoia.io equips clients with the necessary strategies to stay updated and effectively address new challenges. Its approach allows security teams to manage the complexities of cybersecurity with improved speed and reliability, ultimately strengthening their overall security posture.

AB Tasty

Series C in 2020
AB Tasty is a software company that specializes in providing a platform for experimentation, personalization, and product optimization aimed at marketing and product teams. Founded in 2009 and headquartered in Paris, France, the company enables businesses across various sectors, including e-commerce, retail, travel, luxury, media, and financial services, to enhance their digital presence. AB Tasty's platform includes tools for A/B testing, multivariate testing, and user engagement, helping organizations convert website and mobile visitors into customers, subscribers, and leads. By leveraging data on online usage, AB Tasty assists teams in creating optimized user experiences that align with their business objectives, ultimately driving increased conversions and revenue across digital channels.

Enterome

Series E in 2020
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Biofutur

Acquisition in 2020
Biofutur is a network of medical biology analysis laboratories primarily located in France. The organization provides a wide array of services, including medical consultations, hematology, allergology, immunoassays, and embryo transfer, among other related offerings. By focusing on these diverse medical services, Biofutur aims to meet the diagnostic and analytical needs of patients and healthcare professionals in the region.

Dust Mobile

Venture Round in 2019
Dust Mobile is a mobile operator based in Brussels, Belgium, specializing in cyber security solutions for voice, text, and data communications. Established in 2017, the company focuses on protecting its clients from threats associated with cellular network signaling protocols across various technologies, including 2G, 3G, 4G LTE, and 5G. Dust Mobile offers comprehensive services that include encryption for voice, SMS, and data communications, as well as cyber security for mobile networks and transmission. Its mission is to provide secure and resilient mobile communication services to businesses, critical operations, and organizations worldwide, especially for individuals and connected devices that are vulnerable to cyber-attacks. Founded by a team with extensive expertise in defense, security, electronic warfare, and telecommunications, Dust Mobile aims to defend critical communications against an evolving landscape of cyber threats.

TISSIUM

Series B in 2019
TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Solvionic

Venture Round in 2019
Solvionic SA is a technology start-up based in Varilhes, France, specializing in the development and manufacture of ionic liquid chemicals for various commercial and industrial applications. Founded in 2003, the company focuses on sustainable chemistry by employing innovative processes that aim to minimize energy consumption, reduce the use of raw materials, and decrease waste generation. Solvionic's products serve a range of industries, including pharmaceuticals, petrochemicals, energy storage, catalysis, surface treatment, extraction, and biotechnology. By providing improved and safe ionic chemicals, Solvionic aims to meet the demands of its clients in a cost-effective manner while contributing to environmental sustainability.

Biosyl

Venture Round in 2019
Biosyl SAS is a holding company based in Cosne-Cours-sur-Loire, France, founded in 2010. Through its subsidiary, the company specializes in the production of wood pallets for domestic stoves and pallet boilers. Biosyl focuses on transforming waste and wood waste into energy, specifically low-emission wood pellets. The company operates a pellet production plant that processes logs and has the capacity to produce over one hundred thousand tons of pellets annually. This production not only supports local coppice wood recovery but also enables customers to reduce their carbon footprint by utilizing energy derived from low CO2 emissions.

Newronika

Series A in 2019
Newronika is a company focused on restoring brain and body functions through innovative neuro-modulation technologies. It develops therapeutic devices that utilize a retro-activity system to record brain activity and modulate neuro-stimulation. By collecting, analyzing, and interpreting bio-signals, Newronika enables patients to receive timely stimulation, allowing them to engage in normal daily activities and enhance their quality of life. As a spin-off from prominent Italian research institutions, including the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika benefits from a multidisciplinary team of experts in various fields such as neuroscience, neurophysiology, biomedical engineering, and neuropsychology.

Wizaplace

Venture Round in 2019
Wizaplace is a software as a service (SaaS) platform based in Lyon, France, that specializes in the creation and management of various types of marketplaces, including B2C, B2B, and C2C projects, as well as tailored service marketplaces. Founded in 2012, the platform provides an all-in-one solution that integrates essential functions for building and managing marketplaces in a single environment. It features a comprehensive back office for administrators and sellers, alongside a user-friendly front office for clients. Wizaplace aims to democratize the marketplace model by offering customizable options, allowing e-retailers to efficiently develop their e-commerce platforms with ease.

Themis Bioscience

Series D in 2019
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Spherea

Venture Round in 2019
SPHEREA specializes in the design and production of modular testing solutions for various electrical applications, catering to manufacturers, equipment suppliers, integrators, and rail operators. The company offers a range of products including model-based testing systems, field test equipment, wiring testers, and assisted maintenance and repair solutions. SPHEREA's expertise spans the entire life cycle of complex electronic, microwave, optronic, and mechatronic systems, serving critical sectors such as civil aeronautics, defense, energy, and rail both in France and internationally.

Bankin'

Series B in 2019
Bankin' is a mobile application focused on simplifying money management for its users. With a user base of over 1.5 million across France, England, Spain, and Germany, the company prides itself on being the leading independent money management solution in Europe. The app utilizes intelligent algorithms and human coaching to deliver personalized advice related to savings, credit, and insurance, ensuring that customers can manage their finances efficiently. Bankin' emphasizes its commitment to transparency and simplicity, allowing users to concentrate on their priorities without the complications often associated with financial management. By remaining independent of traditional banking institutions, Bankin' aims to provide unbiased guidance tailored to the individual needs of its customers.

NH TherAguix

Series A in 2019
NH TherAguix SAS is a clinical stage pharmaceutical company based in Villeurbanne, France, focused on developing nanomedicines for cancer treatment, specifically utilizing radiotherapy. The company's lead product, AGuIX, is a theranostic nanoparticle designed to enhance the localization of solid tumors and improve the effectiveness of radiation therapy. AGuIX allows for the determination of optimal irradiation timing and is capable of treating radioresistant cancers while minimizing radiation exposure to healthy tissues, thereby reducing secondary effects. Founded in 2015, NH TherAguix is dedicated to advancing innovative solutions in cancer care through its pioneering research and development efforts.

AgomAb Therapeutics

Series A in 2019
AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Therapixel

Series A in 2019
Therapixel SA is a French company specializing in the development of artificial intelligence-based medical image analytics software aimed at enhancing surgical procedures. Founded in 2013 and headquartered in Valbonne, France, Therapixel offers a range of products designed to assist healthcare professionals, including Radvise, an automatic image reading solution; Fluid, a touchless navigation system for surgical environments; Anywhere, a post-processing workstation; and CD-Feed, a solution for importing outpatient imaging exams. The company's technology focuses on providing timely and relevant information to surgeons, ensuring they can access critical medical images before or during surgical operations. With additional locations in various countries, including Australia, China, and several nations across Europe and Latin America, Therapixel is committed to improving breast cancer detection and characterization through its innovative software solutions.

Teach on Mars

Venture Round in 2019
Teach on Mars SAS is a prominent provider of mobile-led learning technology based in France, with offices in Sophia Antipolis, Paris, Milan, and London. Founded in 2013, the company has established itself as a leader in the mobile learning sector, delivering innovative solutions to over 100 clients across more than 60 countries. Their platform enables trainers to design mobile courses and learning games, manage training progress, and analyze learning metrics through a user-friendly interface accessible on smartphones and tablets. Additionally, Teach on Mars offers various services, including mobile learning training, certification, app marketing, and integration with professional content marketplaces. The company's commitment to social responsibility is reflected in its investment of 1% of revenues into education projects that align with the UN Sustainable Development Goals.

Bizay

Series B in 2018
BIZAY operates a digital marketplace that specializes in customizable products, catering to a diverse range of customers across Europe and the Americas. The company offers the world's largest catalogue of customizable items, allowing local manufacturers, brands, and wholesalers to deliver personalized products efficiently. Its platform targets various customer segments, including B2B2C businesses, small and medium-sized enterprises, and major brands seeking customized solutions. BIZAY’s extensive offerings encompass promotional items, packaging, home and garden goods, fashion products, and beauty items. The company emphasizes sustainability and social responsibility by collaborating with partners focused on inclusion and utilizing recycled materials in production. BIZAY employs advanced supply-chain optimization technologies to significantly reduce production costs, empowering clients to enhance their marketing strategies through innovative customization options.

ABMI

Venture Round in 2018
ABMI is an engineering company that specializes in providing a range of solutions including design, IT infrastructure, robotics, Internet of Things (IoT), cloud computing, and cybersecurity. The company operates as a multi-specialist in a rapidly growing market, focusing on innovative technologies to meet the needs of its clients.

Captain Tortue

Funding Round in 2018
Captain Tortue is the European leader in direct selling women's ready-to-wear clothing. Every year, it designs around 330 models through its four brands: Trend (trendy collection, urban chic), Miss (classic and casual collection), Little Miss (children's collections, teenagers and small sizes) and Java (home wear comfort-casual).

Sentryo

Series A in 2018
Sentryo SAS specializes in cybersecurity and situational awareness solutions tailored for industrial networks and the Internet of Things. Founded in 2014 and headquartered in Charbonnières-les-Bains, France, the company focuses on enhancing the resilience and safety of industrial operations by providing continuous visibility over Industrial Control Systems (ICS) and SCADA infrastructures. Sentryo's flagship product, ICS CyberVision, empowers control engineers to monitor all equipment connected to industrial networks, identifying vulnerabilities and enabling informed decision-making to maintain system integrity. The company's solutions integrate artificial intelligence and machine learning to deliver real-time insights, analyze alarms, and enhance infrastructure security, thereby helping corporations mitigate the risks of cyberattacks. As of 2019, Sentryo operates as a subsidiary of Cisco Systems, Inc.

Intersec

Venture Round in 2018
Intersec SA, established in 2004, is a global technology company headquartered in Paris, France, with an additional office in London, UK. It specializes in providing real-time, streaming analytics solutions to various sectors, including telecommunications, utilities, manufacturing, financial services, and retail. Intersec's offerings encompass customer base management, location data monetization, fraud management, public safety, IoT analytics, and messaging solutions. With a client base of 90 organizations across 40 countries, Intersec's solutions enable the tracking and mapping of nearly one billion connected devices worldwide, 24/7. The company's mission-critical communication solutions cover 400 million people globally. Recognized by Gartner® as a leading vendor in location intelligence, spatial computing, and telecom data monetization, Intersec prioritizes privacy and regulatory compliance, ensuring it operates in line with the highest standards.

GEEV

Venture Round in 2018
GEEV is a mobile application that facilitates the donation and collection of various objects among its users, promoting a collaborative anti-waste initiative. It allows members to either give away items they no longer need or to obtain free objects from others, thereby encouraging sustainable practices and reducing waste. The platform includes features that enable users to communicate easily, arrange meetings, and effectively exchange items, fostering a community-driven approach to sharing resources. By connecting individuals who wish to donate with those seeking to obtain, GEEV aims to give a second life to usable items while minimizing environmental impact.

Antabio

Series A in 2018
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Marquetis

Debt Financing in 2018
Marquetis & Co, founded in 1996 and based in Boulogne Billancourt, France, operates as a comprehensive marketing and communications agency. Under the leadership of Virginie Massa and Evangelos Vatzias, the company has developed a range of services through its subsidiaries, including Marquetis One, Marquetis Connect, and Marquetis Call. Marquetis specializes in operational marketing, offering clients an integrated approach that encompasses global communication consulting and automated cross-channel marketing delivered in a SaaS format. The agency focuses on relational branding strategies, providing strategic, creative, digital, and customer contact advisory services. By utilizing predictive performance models, Marquetis aids clients in enhancing their brand strategies and achieving their marketing objectives.

Tiller Systems

Series B in 2018
Tiller Systems SAS is a Paris-based company that specializes in developing cloud-based point of sale (POS) software solutions for restaurants and merchants. Founded in March 2014, Tiller's management tools enable users to accept various payment types, integrate partner applications, and effectively oversee staff and inventory in real time. The software features a mobile POS system that allows for the management of both in-store and online orders from a single platform. Additionally, Tiller offers a web dashboard that facilitates catalog updates, sales tracking, employee payments, stock alerts, customer relationship management, and access to real-time reporting and performance metrics. With additional offices in Barcelona and Milan, Tiller Systems aims to empower businesses to make informed decisions and enhance their operational efficiency.

Mistral Informatique

Acquisition in 2018
The Mistral group markets an integrated software solution (ERP) dedicated to the market and the business of dealers, renters, resellers of agricultural equipment and construction equipment. The group consists of two entities, Mistral Informatique (publisher of software and mobility applications) and Mistral DataCenter (hosting and outsourcing services).

Nanomakers

Venture Round in 2018
Nanomakers is a Paris-based company founded in 2010 that specializes in the design, manufacture, and marketing of silicon-based nanopowders. These patented, nano-scale powders are utilized to enhance the mechanical reinforcement of materials such as metal alloys and elastomers, as well as to improve the energy storage density of lithium-ion batteries through silicon-carbon composites in anodes. The company's nanopowders, including silicon carbide and silicon, significantly enhance the mechanical, thermal, and chemical performance of various industrial materials. Nanomakers serves multiple sectors, including semiconductors, energy storage, aeronautics, space, and automotive industries, by providing innovative solutions that contribute to advancements in technology and material performance.

Tilkee

Series A in 2018
Tilkee is a cloud-based application that enhances the efficiency of sales teams by tracking business proposals and optimizing follow-up with prospects. The platform allows users to easily upload sales documents and create branded online proposals. Once a unique link is generated for each prospect, Tilkee monitors their reading behavior, providing real-time notifications about who has engaged with the documents, which sections received the most attention, and the duration of their engagement. This data-driven approach helps sales professionals assess prospects' readiness to close deals, thereby increasing closing rates and improving overall marketing effectiveness.

Scality

Series E in 2018
Scality, Inc. is a leading provider of software-defined storage solutions, specializing in active archives, content distribution, and cloud services. Founded in 2009 and headquartered in San Francisco, with an additional office in Cambridge, Massachusetts, the company developed RING, a scalable software-based storage system capable of managing petabytes of data. RING supports high-performance, parallel processing, and integrates seamlessly with various applications through standard storage protocols such as NFS and S3. This innovative storage architecture delivers billions of files to hundreds of millions of users daily, ensuring 100% availability and reducing operational costs. Scality serves a diverse range of clients, including major media and telecommunications companies, as well as leading firms across the U.S., Europe, and Japan. The company is recognized for its ability to help enterprises and service providers effectively address the challenges of large-scale data storage.

ForCity

Series A in 2018
ForCity is a software-as-a-service company specializing in 4D urban simulation to aid decision-making in the development of smart cities. The firm has developed a decision support platform that enhances strategic planning and operational efficiency by integrating various datasets related to urban parameters such as energy consumption, water usage, real estate projects, and land availability. Using advanced 3D and 4D simulation techniques, the platform generates detailed reports that assist municipal managers in optimizing development strategies across areas like energy management, waste disposal, land use, and economic growth. This innovative approach enables municipalities to make informed decisions that contribute to sustainable urban development.

VSORA

Series A in 2018
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

Pherecydes Pharma

Series B in 2018
Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Enterome

Debt Financing in 2018
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Themis Bioscience

Series C in 2018
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Coave Therapeutics

Series B in 2017
Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Aero Negoce International

Venture Round in 2017
Aero Negoce International, SAS is a manufacturer and distributor of fasteners and hardware specifically for the aerospace industry. Founded in 1993 and headquartered in Béziers, France, the company offers a diverse range of products, including fasteners, spherical plain bearings, connectors, lamps, seals, and hinges. In addition to its manufacturing capabilities, Aero Negoce International provides services such as contract management, consignment stock, and custom packing. The company primarily serves major aircraft manufacturers like Airbus and Dassault, as well as key suppliers in the aerospace sector, including Zodiac and Safran.

Groupe InCa

Acquisition in 2017
Groupe InCa SAS, founded in 1954 and headquartered in Artigues Près Bordeaux, France, is a prominent player in the construction industry within the New Aquitaine region. The company specializes in the building of custom-designed detached homes, catering to a diverse clientele that includes both first-time buyers and high-end customers. It operates under three well-established brands: Maisons Clairlande, Les Demeures de la Côte d’Argent, and Rouquié Constructions. Through its focus on quality and tailored solutions, Groupe InCa has positioned itself as a regional leader in the residential construction market.

Groupe InCa

Acquisition in 2017
Groupe InCa SAS, founded in 1954 and headquartered in Artigues Près Bordeaux, France, is a prominent player in the construction industry within the New Aquitaine region. The company specializes in the building of custom-designed detached homes, catering to a diverse clientele that includes both first-time buyers and high-end customers. It operates under three well-established brands: Maisons Clairlande, Les Demeures de la Côte d’Argent, and Rouquié Constructions. Through its focus on quality and tailored solutions, Groupe InCa has positioned itself as a regional leader in the residential construction market.

AB Tasty

Series B in 2017
AB Tasty is a software company that specializes in providing a platform for experimentation, personalization, and product optimization aimed at marketing and product teams. Founded in 2009 and headquartered in Paris, France, the company enables businesses across various sectors, including e-commerce, retail, travel, luxury, media, and financial services, to enhance their digital presence. AB Tasty's platform includes tools for A/B testing, multivariate testing, and user engagement, helping organizations convert website and mobile visitors into customers, subscribers, and leads. By leveraging data on online usage, AB Tasty assists teams in creating optimized user experiences that align with their business objectives, ultimately driving increased conversions and revenue across digital channels.

Batiweb.com

Venture Round in 2017
Batiweb.com is a B2B web portal dedicated to the housing and construction sectors, positioning itself as a key player in the market. The platform serves as a digital networking hub that connects trade professionals with consumers, offering essential information on construction, renovation, and housing-related issues. Batiweb operates through three main activities: intermediation, media, and various services, which collectively address the needs of clients in the construction industry. By continuously expanding its product offerings, Batiweb aims to establish itself as the leading online group focused on construction, housing, and decoration.

RGF GROUP

Acquisition in 2017
RGF Group is a manufacturer specializing in plastic injection molding, catering to various sectors such as healthcare, sports, construction, home automation, automotive, and industrial equipment. The company utilizes advanced technology, including electric and hydraulic machines, to offer both single and bi-material injection solutions. In addition to manufacturing, RGF Group provides expertise in the design and production of injection tooling, ensuring high-quality and efficient service. With production facilities located in France and globally, RGF Group emphasizes flexibility and responsiveness to meet the industrial challenges of its clients.

MultiX

Venture Round in 2017
MultiX S.A. is a French company established in 2010, specializing in the design, production, and sale of advanced spectrometric X-ray detectors. These detectors are primarily used for identifying materials across various sectors, including security, food processing, mining, recycling, and other non-destructive testing applications. MultiX's technology enhances the capabilities of system manufacturers, enabling them to significantly reduce false alarm rates in baggage screening systems at airports and other sensitive locations. This improvement allows airport operators to streamline passenger experiences by minimizing the need for travelers to remove liquids and laptops from their hand luggage, all while adhering to stringent security regulations. By providing efficient and reliable detection solutions, MultiX supports integrators in enhancing operational efficiency and passenger comfort.

Circet

Venture Round in 2017
Circet, a leading French company, specializes in constructing, maintaining, and repairing fixed and mobile telecommunication networks for major operators and large user accounts. It is renowned for its agile and flexible turnkey solutions, focusing on process industrialization and efficient management of these services.

Octimet Oncology

Series A in 2017
Octimet Oncology NV is a biotechnology company based in Beerse, Belgium, established in 2016. The company focuses on developing MET kinase inhibitors and other selective anti-tumor molecules aimed at treating various types of cancer. Octimet employs innovative patient selection and pharmacodynamic biomarker-based strategies to enhance the development of its discovery-stage molecules. By utilizing these advanced methods, Octimet aims to differentiate its treatments from existing options in the market, ensuring that patients receive targeted therapies for solid tumors. The company's strategic approach emphasizes clinical development that leverages biomarker-defined intelligent patient selection, ultimately striving to improve treatment outcomes for cancer patients.

Bankin'

Series A in 2017
Bankin' is a mobile application focused on simplifying money management for its users. With a user base of over 1.5 million across France, England, Spain, and Germany, the company prides itself on being the leading independent money management solution in Europe. The app utilizes intelligent algorithms and human coaching to deliver personalized advice related to savings, credit, and insurance, ensuring that customers can manage their finances efficiently. Bankin' emphasizes its commitment to transparency and simplicity, allowing users to concentrate on their priorities without the complications often associated with financial management. By remaining independent of traditional banking institutions, Bankin' aims to provide unbiased guidance tailored to the individual needs of its customers.

Enterome

Series D in 2017
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Themis Bioscience

Series B in 2016
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Ducatillon

Acquisition in 2016
Ducatillon is a retailer focused on the internet distribution of breeding equipment and outdoor leisure goods, catering to hobby farmers and families with pets, poultry, rabbits, goats, and sheep. The company also offers a range of equipment and accessories tailored for hunting enthusiasts and their hunting dogs. By specializing in branded and durable products, Ducatillon aims to meet the needs of its customers in the recreational goods sector.

Oxatis

Series D in 2016
Oxatis SA is a provider of e-commerce technology solutions based in Marseille, France, established in 2001. The company specializes in offering Software as a Service (SaaS) tools designed for small businesses to create comprehensive websites and establish an online presence. Its offerings include online content management system (CMS) software, hosting services, and integrated shopping cart solutions. These tools enable users to sell products online with minimal technical expertise and investment, making e-commerce accessible to a broader range of entrepreneurs.

Bizay

Series A in 2016
BIZAY operates a digital marketplace that specializes in customizable products, catering to a diverse range of customers across Europe and the Americas. The company offers the world's largest catalogue of customizable items, allowing local manufacturers, brands, and wholesalers to deliver personalized products efficiently. Its platform targets various customer segments, including B2B2C businesses, small and medium-sized enterprises, and major brands seeking customized solutions. BIZAY’s extensive offerings encompass promotional items, packaging, home and garden goods, fashion products, and beauty items. The company emphasizes sustainability and social responsibility by collaborating with partners focused on inclusion and utilizing recycled materials in production. BIZAY employs advanced supply-chain optimization technologies to significantly reduce production costs, empowering clients to enhance their marketing strategies through innovative customization options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.